Celcuity Inc. (CELC) Stock AnalysisCELCCelcuity Inc.

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Celcuity Inc. (CELC) is currently trading at $88.44, which is significantly below the analyst price targets of $155 to $178. However, the stock has a low RSI of 37.83, indicating it may be oversold, but its recent performance shows a 5-day decline of 5.44%. The company has submitted a supplemental new drug application for REVTORPYK, which could enhance its market position if approved. The main risk is its ongoing negative net income, which reached -$78,864,000 in Q2 2026, indicating financial instability.

1 analysts cover CELC: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 106.50.